Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Placebo Controlled, Double-Blind, Randomized, Discontinuation Study of Lapatinib Administered Orally to Subjects With ErbB2 Positive Ovarian, Gastric/Esophageal Adenocarcinoma, Uterine Serous Papillary, or Bladder Cancer

NCT00447226 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT00447226
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00447226 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Placebo Controlled, Double-Blind, Randomized, Discontinuation Study of Lapatinib Administered Orally to Subjects With ErbB2 Positive Ovarian, Gastric/Esophageal Adenocarcinoma, Uterine Serous Papillary, or Bladder Cancer
Lead sponsor
GlaxoSmithKline
Phase
Phase 2
Overall status
Terminated
Start date
May 31, 2007
Completion date
September 30, 2009
Enrollment
32 (actual)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

cancer